Journal
MICROBES AND INFECTION
Volume 16, Issue 6, Pages 512-517Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.micinf.2014.02.011
Keywords
Bacteriophage; Mouse; Podoviridae; Therapeutic; Therapy
Categories
Funding
- Center for Innovative and Translational Medicine, Kochi System Glycobiology Center [24791025]
- Center of Biomembrane Functions Controlling Biological Systems, Kochi University, Kochi, Japan
- Grants-in-Aid for Scientific Research [26461504, 23591478, 24791025] Funding Source: KAKEN
Ask authors/readers for more resources
Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacterernia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available